Homas Bold Leeds Renovacare, Inc.'s New R&D Innovation Center
July 01, 2020 at 01:30 pm
Share
RenovaCare, Inc. announced the official launch of its new RenovaCare R&D Innovation Center in Berlin, Germany, where the Company’s patented technologies for isolating and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives. The RenovaCare R&D Innovation Center will be led by Mr. Thomas Bold, an inventor of several RenovaCare technologies and long-serving Advisor to the Company. Notably, Mr. Bold served as President and CEO of RenovaCare from 2013 to 2018, and previously was President at StemCell Systems, home of the new Innovation Center.
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.
RENOVACARE, INC. 
